Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$7.91M | -$19.6M | -$45.2M | -$61.1M | -$114M | -$124M |
| Net income | -$7.33M | -$101M | -$42.9M | -$52.4M | -$102M | -$121M |
| EPS (diluted) | -$17.48 | -$5.02 | -$1.06 | -$1.08 | -$1.71 | -$2.00 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.45M | -$18.0M | -$35.2M | -$43.1M | -$86.2M | -$116M |
| Capital expenditures | — | $40.0K | $161K | $21.0K | $16.0K | $88.0K |
| Free cash flow | — | -$18.0M | -$35.3M | -$43.1M | -$86.2M | -$116M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $43.8M | $122M | $130M | $66.9M | $35.6M | $54.0M |
| Total assets | $44.4M | $230M | $197M | $310M | $239M | $123M |
| Total liabilities | $6.37M | $5.15M | $7.81M | $43.2M | $57.2M | $52.4M |
| Long-term debt | — | — | $0.00 | $29.9M | $29.4M | $22.4M |
| Shareholders' equity | -$18.6M | $225M | $189M | $267M | $182M | $70.4M |
| Retained earnings | -$27.0M | -$128M | -$170M | -$223M | -$325M | -$446M |
| Shares (wtd avg diluted) | 419K | 20.1M | 40.6M | 48.6M | 60.0M | 60.6M |
Every figure is extracted from Acumen Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.